Drugs / C difficile vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01706367 | Sep 2012 → Jan 2014 | Clostridium difficile colitis | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07282665 | Dec 2025 → Dec 2028 expected | Clostridium difficile colitis | Pfizer | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-01-26 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection pfizer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C difficile vaccine | “This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50...” NCT01706367 ↗ |
| Known as | Clostridium difficile vaccine | “A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum...” PMID 26993331 ↗ Mar 2016 |
| Modality | Vaccine | “an investigational vaccine candidate consisting of genetically and chemically detoxified, purified toxins A and B” PMID 26993331 ↗ Mar 2016 |
| Route | Intramuscular | “C.difficile vaccine given as an intramuscular injection” NCT07282665 ↗ |